Previous Study: TRIO 012
Next Study: BCIRG 002

Studies & Results

BCIRG 001

A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil in combination with doxorubicin and cyclophosphamide (FAC) as adjuvant treatment of operable breast cancer patients with positive axillary lymph nodes.

View FDA Study

Presentations

ASCO Annual Meeting, 2007

Dumontet C, Reed J, Krajewska M, et al.

Identification of prognostic factors in patients ( pts ) receiving adjuvant therapy for node - positive (N+) Breast Cancer (BC)

San Antonio Breast Cancer Symposium, 2010

Martin M, Mackey J, Pienkowski T, et al:

Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer. Dumontet C, Reed C, Krajewska M, et al: Identification of prognostic factors in patients ( pts ) receiving adjuvant therapy for node - positive (N+) Breast Cancer (BC), ASCO Annual Meeting 2007.

ASCO Annual Meeting, 2004

Vogel CL, Mackey JR, Martin M

The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001.

ASCO Annual Meeting, 2002

Nabholtz JM, Pienkowski T, Mackey J

Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fl uorouracil,doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: Interim analysis of the BCIRG 001.

Publications

Mackey JR, Martin M, Pienkowski T, et al: Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72–80, 2013

Pajares B, Pollán M, Martín M, et al: Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res BCR 15:R105, 2013

Dumontet C, Krajewska M, Treilleux I, et al: BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 16:3988–3997, 2010

Au H-J, Golmohammadi K, Younis T, et al: Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat 114:579–587, 2009

Hugh J, Hanson J, Cheang MCU, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol Off J Am Soc Clin Oncol 27:1168–1176, 2009

Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313, 2005

Nabholtz J-MA, Reese DM, Lindsay M-A, et al: Docetaxel in the treatment of breast cancer: an update on recent studies. Semin Oncol 29:28–34, 2002

Nabholtz JM, Mackey JR, Smylie M, et al: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 19:314–321, 2001

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org